Hemangioblast-Derived MSC Culture for Potency-Retaining Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving mesenchymal stromal cells (MSCs) from pluripotent cells, such as embryonic stem cells, are inefficient, yield low-quality cells, and result in senescence due to replicative stress, affecting their therapeutic potency and safety for clinical applications.
Innovation Solution
Culturing hemangioblast cells under specific conditions to differentiate into mesenchymal stromal cells, characterized by upregulated CD24 mRNA and low IL-6 expression, reduced clumping, enhanced dispersibility, and earlier acquisition of mesenchymal markers, resulting in higher potency and number compared to MSCs derived directly from pluripotent cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MSCs are derived directly from pluripotent cells using conventional methods, then cell production is achieved, but the cells exhibit senescence, low quality, and reduced therapeutic potency
Solution Approach 1:
The patent introduces hemangioblasts as an intermediary cell type between pluripotent cells and mesenchymal stromal cells. By differentiating pluripotent cells into hemangioblasts first, and then into MSCs, the method avoids direct differentiation issues that cause senescence and low quality. This two-step differentiation process through a mediator cell type resolves the contradiction between producing cells and maintaining their therapeutic potency.
Solution Approach 2:
The patent applies preliminary action by first differentiating pluripotent cells into hemangioblasts before further differentiating them into MSCs. This preliminary differentiation step prepares the cells in a controlled manner, preventing replicative stress and senescence that would otherwise occur during direct differentiation or excessive passaging. The preliminary action of forming hemangioblasts ensures subsequent MSCs maintain high quality and therapeutic potency.
2Quantity of substance
If MSCs undergo sequential ex-vivo expansion to reach clinically meaningful numbers, then sufficient cell quantity is produced, but replicative stress and chromosomal abnormalities occur, reducing safety and efficacy
Solution Approach 1:
The patent performs preliminary differentiation of pluripotent cells into hemangioblasts before expansion. This preliminary action creates a cell population that can be expanded without undergoing the replicative stress and senescence that plague conventional MSC expansion. By establishing the hemangioblast intermediate stage first, subsequent expansion produces MSCs that maintain chromosomal stability and safety even at high cell numbers required for clinical applications.
Solution Approach 2:
Hemangioblasts serve as an intermediary that enables safe expansion. The patent uses hemangioblasts as a mediator between pluripotent cells and final MSC product, allowing expansion to occur at the hemangioblast stage where replicative stress is minimized. This intermediary approach ensures that when MSCs are finally generated from expanded hemangioblasts, they maintain clinical safety and efficacy despite the large expansion required.
3Productivity
If conventional MSC derivation methods are used, then cells can be obtained, but the process is inefficient with low yield and varying quality
Solution Approach 1:
The patent introduces hemangioblasts as a standardized intermediary cell type that improves both yield and quality consistency. By routing all differentiations through the hemangioblast stage, the method creates a consistent manufacturing pathway that produces high-quality MSCs with uniform characteristics. This intermediary approach eliminates the variability and low yield associated with direct differentiation methods.
Solution Approach 2:
The patent employs parameter changes by controlling differentiation conditions at each stage (pluripotent cells to hemangioblasts, then hemangioblasts to MSCs). By optimizing and controlling the parameters of each differentiation step, the method achieves high yield and consistent quality. The parameter changes in culture conditions, growth factors, and timing at each stage ensure reproducible production of high-quality MSCs.
4Loss of energy
If immunomodulatory therapies are withdrawn after initial success, then treatment costs are reduced, but the pathology reverts to unwanted state
Solution Approach 1:
The patent employs self-service by engineering MSCs that autonomously provide immunomodulatory function without requiring external support or continuous therapy. The modified MSCs express cytokines and immune-regulating molecules that enable them to independently control immune responses and maintain therapeutic effect long after administration. This self-service capability eliminates treatment dependency while maintaining long-term efficacy, as the cells continuously provide immunomodulation without needing repeated dosing or external immunomodulatory agents.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies.